Glioblastoma Platelet Activation Study (GPAS)

University Medicine Greifswald

Status: Completed

Conditions: Glioblastoma; Circulating Platelet-monocyte Conjugates

Study type: Observational

Funder types: Other

Identifiers

NCT02887417

Glioma-HGW

Details and patient eligibility

About

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Full description

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Enrollment: 21 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• MR-morphological suspicion for glioblastoma
• informed consent

Exclusion criteria

• no informed consent

Trial design

21 participants in 2 patient groups

patients

Description:

glioblastoma patients

controls

Description:

healthy controls